Health Care · Biotechnology

Ardelyx, Inc. ARDX

$5.09+0.03 (+0.49%)delayed quote · as of 2026-07-29 10:42 UTC

Open ARDX in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$1.3B

Previous close

$5.06

Volume

1.6M

52-week range

$4.08 – $8.40

Verdictconfidence 69% · moderate

Growing fast on a stretched balance sheet.

2 of 5 dimensions score well; health flashes caution. Value and Momentum not scored — not enough data.

Value—0/2 checks

Growth753/4 checks

Quality603/5 checks

Health402/5 checks

Momentum—0/2 checks

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

—

P/E FWD

9.9

EV/EBITDA TTM

—

PEG

—

FCF yield TTM

-3.0%

Growth

Revenue 3y

+98.4%/yr

Revenue YoY

+22.1%

Expected EPS

—

Quality

Piotroski F

3 / 9

ROIC

-13.2%

Gross margin

90.3%

Health

Altman Z

0.85

Current ratio

4.31

Debt/equity

1.21

Momentum

vs 50-day

—

vs 200-day

—

52-wk range

23%

FY 2025: revenue $407.3M · net income -$61.6M · free cash flow -$44.0M (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-29 10:42 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading ARDX’s filed statements…

Continue with ARDX in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.